Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONITIN MIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONITIN MIST.
AQUAPHYLLIN vs BRONITIN MIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Primarily renal (approximately 70-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Bronchodilator
Bronchodilator